// App-Quantinova.ai

1638 : CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

Researchers

Presenter

  • Anas Younes

Principal Investigators

  • Sven De Vos

  • R. Gregory Bociek

  • Leo I. Gordon

  • Thomas E. Witzig

  • Randy D. Gascoyne

  • Brian West

  • Keith Nolop

  • Christian Steidl

Medical Centers

  • Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

  • Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Department of Medical Oncology, BC Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • Plexxikon Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hodgkin's Lymphoma

  • Neutropenia

  • Lymphomas

  • Anemia

Biomarkers

  • Cluster of Differentiation 163

  • Colony stimulating factor 1

  • Colony stimulating factor 1 receptor

  • Lactate dehydrogenase

Drug/Treatment

  • L-Tyrosine

  • Pexidartinib

  • Cilmostim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved